Dybbs Michael

Dybbs Michael is listed in filings as Director at Kalaris Therapeutics Inc. This profile follows SEC Form 4 activity through Jun 4, 2026, including 5 public disclosures. Recent filings connect the profile to Kalaris Therapeutics Inc (KLRS), Sutro Biopharma, Inc. (STRO), and Nkarta, Inc. (NKTX). The current snapshot covers public activity from Jun 14, 2024 to Jun 4, 2026. Reported amounts are shown as $42.5K to $84.2K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.